Multiple, linked human immunodeficiency virus type 1 drug resistance mutations in treatment-experienced patients are missed by standard genotype analysis

Journal of Clinical Microbiology

Volumn 43, Issue 1, 2005, Pages 406-413

  Palmer, Sarah ^a   Kearney, Mary ^a   Maldarelli, Frank ^a   Halvas, Elias K ^e   Bixby, Christian J ^e   Bazmi, Holly ^b   Rock, Diane ^c   Falloon, Judith ^c   Davey Jr , Richard T ^c   Dewar, Robin L ^b   Metcalf, Julia A ^c   Hammer, Scott ^d   Mellors, John W ^e   Coffin, John M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COMPLEMENTARY DNA; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE AMPLIFICATION; GENE MUTATION; GENE SEQUENCE; GENETIC LINKAGE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERMETHOD COMPARISON; LINKAGE ANALYSIS; MULTIDRUG RESISTANCE; MUTATIONAL ANALYSIS; PHYLOGENETIC TREE; PLASMA; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; VIRUS GENE;

ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; GENOME, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SEQUENCE ANALYSIS, DNA;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; RNA VIRUSES;

EID: 19944428265     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.43.1.406-413.2005     Document Type: Article

References (48)

1. Albrecht, D., B. Zollner, H. H. Feucht, T. Lorenzen, R. Laufs, A. Stoehr, and A. Plettenberg. 2002. Reappearance of HIV multidrug-resistance in plasma and circulating lymphocytes after reintroduction of antiretroviral therapy. J. Clin. Virol. 24:93-98.
2. Bacheler, L. T., E. D. Anton, P. Kudish, D. Baker, J. Bunville, K. Krakowski, L. Bolling, M. Aujay, X. V. Wang, D. Ellis, M. F. Becker, A. L. Lasut, H. J. George, D. R. Spalding, G. Hollis, and K. Abremski. 2000. Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob. Agents Chemother. 44:2475-2484.
3. Baxter, J. D., D. L. Mayers, D. N. Wentworth, J. D. Neaton, M. L. Hoover, M. A. Winters, S. B. Mannheimer, M. A. Thompson, D. I. Abrams, B. J. Brizz, J. P. Ioannidis, T. C. Merigan, et al. 2000. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. AIDS 14:F83-F93.
4. Brown, A. J., and A. Cleland. 1996. Independent evolution of the env and pol genes of HIV-1 during zidovudine therapy. AIDS 10:1067-1073.
5. Carpenter, C. C., M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, M. A. Thompson, S. Vella, P. G. Yeni, and P. A. Volberding. 1997. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society-USA panel. JAMA 277:1962-1969.
6. Charpentier, C., D. E. Dwyer, F. Mammano, D. Lecossier, F. Clavel, and A. J. Hance. 2004. Role of minority populations of human immunodeficiency virus type 1 in the evolution of viral resistance to protease inhibitors. J. Virol. 78:4234-4247.
7. Chenna, R., H. Sugawara, T. Koike, R. Lopez, T. J. Gibson, D. G. Higgins, and J. D. Thompson. 2003. Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 31:3497-3500.
8. Coffin, J. M. 1995. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science 267:483-489.
9. Condra, J. H., D. J. Holder, W. A. Schleif, O. M. Blahy, R. M. Danovich, L. J. Gabryelski, D. J. Graham, D. Laird, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, T. Yang, J. A. Chodakewitz, P. J. Deutsch, R. Y. Leavitt, F. E. Massari, J. W. Mellors, K. E. Squires, R. T. Steigbigel, H. Teppler, and E. A. Emini. 1996. Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J. Virol. 70:8270-8276.
10. Condra, J. H., W. A. Schleif, O. M. Blahy, L. J. Gabryelski, D. J. Graham, J. C. Quintero, A. Rhodes, H. L. Robbins, E. Roth, M. Shivaprakash, D. Titus, T. Yang, H. Teppler, K. E. Squires, P. J. Deutsch, and E. A. Emini. 1995. In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 374:569-571.
11. Deeks, S. G., T. Wrin, T. Liegler, R. Hoh, M. Hayden, J. D. Barbour, N. S. Hellmann, C. J. Petropoulos, J. M. McCune, M. K. Hellerstein, and R. M. Grant. 2001. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N. Engl. J. Med. 344:472-480.
12. DeGruttola, V., L. Dix, R. D'Aquila, D. Holder, A. Phillips, M. Ait-Khaled, J. Baxter, P. Clevenbergh, S. Hammer, R. Harrigan, D. Katzenstein, R. Lanier, M. Miller, M. Para, S. Yerly, A. Zolopa, J. Murray, A. Patick, V. Miller, S. Castillo, L. Pedneault, and J. Mellors. 2000. The relation between baseline HIV drug resistance and response to antiretroviral therapy: reanalysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5:41-48.
13. Delaugerre, C., M. A. Valantin, M. Mouroux, M. Bonmarchand, G. Carcelain, C. Duvivier, R. Tubiana, A. Simon, F. Bricaire, H. Agut, B. Autran, C. Katlama, and V. Calvez. 2001. Re-occurrence of HIV-1 drug mutations after treatment re-initiation following interruption in patients with multiple treatment failure. AIDS 15:2189-2191.
14. Demeter, L. M., R. D'Aquila, O. Weislow, E. Lorenzo, A. Erice, J. Fitzgibbon, R. Shafer, D. Richman, T. M. Howard, Y. Zhao, E. Fisher, D. Huang, D. Mayers, S. Sylvester, M. Arens, K. Sannerud, S. Rasheed, V. Johnson, D. Kuritzkes, P. Reichelderfer, A. Japour, et al. 1998. Interlaboratory concordance of DNA sequence analysis to detect reverse transcriptase mutations in HIV-1 proviral DNA. Virol. Methods 75:93-104.
15. Durant, J., P. Clevenbergh, P. Halfon, P. Delgiudice, S. Porsin, P. Simonet, N. Montagne, C. A. Boucher, J. M. Schapiro, and P. Dellamonica. 1999. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial. Lancet 353:2195-2199.
16. Dykes, C., J. Najjar, R. J. Bosch, M. Wantman, M. Furtado, S. Hart, S. M. Hammer, and L. M. Demeter. 2004. Detection of drug-resistant minority variants of HIV-1 during virologic failure of indinavir, lamivudine, and zidovudine. J. Infect. Dis. 189:1091-1096.
17. EuroGuidelines Group for HIV Resistance. 2001. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS 15:309-320.
18. Gunthard, H. F., J. K. Wong, C. C. Ignacio, D. V. Havlir, and D. D. Richman. 1998. Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Res. Hum. Retrovir. 14:869-876.
19. Hammer, S. M., F. Vaida, K. K. Bennett, M. K. Holohan, L. Sheiner, J. J. Eron, L. J. Wheat, R. T. Mitsuyasu, R. M. Gulick, F. T. Valentine, J. A. Aberg, M. D. Rogers, C. N. Karol, A. J. Saah, R. H. Lewis, L. J. Bessen, C. Brosgart, V. DeGruttola, and J. W. Mellors. 2002. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial. JAMA 288:169-180.
20. Hance, A. J., V. Lemiale, J. Izopet, D. Lecossier, V. Joly, P. Massip, F. Mammano, D. Descamps, F. Brun-Vezinet, and F. Clavel. 2001. Changes in human immunodeficiency virus type 1 populations after treatment interruption in patients failing antiretroviral therapy. J. Virol. 75:6410-6417.
21. Havlir, D. V., S. Eastman, A. Gamst, and D. D. Richman. 1996. Nevirapine-resistant human immunodeficiency virus: kinetics of replication and estimated prevalence in untreated patients. J. Virol. 70:7894-7899.
22. Holmes, E. C., L. Q. Zhang, P, Simmonds, C. A. Ludlam, and A. J. Brown. 1992. Convergent and divergent sequence evolution in the surface envelope glycoprotein of human immunodeficiency virus type 1 within a single infected patient. Proc. Natl. Acad. Sci. USA 89:4835-4839.
23. Holterman, L., R, Dubbes, J. Mullins, J. Haaijman, and J. Heeney. 2000. A strategy for cloning infectious molecular clones of retroviruses from serum or plasma. J. Virol. Methods 84:37-48.
24. Kuiken, C., B. Korber, and R. W. Shafer. 2003. HIV sequence databases. AIDS Rev. 5:52-61.
25. Lawrence, J., D. L. Mayers, K. H. Hullsiek, G. Collins, D. I. Abrams, R. B. Reisler, L. R. Crane, B. S. Schmetter, T. J. Dionne, J. M. Saldanha, M. C. Jones, and J. D. Baxter. 2003. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N. Engl. J. Med. 349:837-846.
26. Learn, G. H., D. Muthui, S. J. Brodie, T. Zhu, K. Diem, J. I. Mullins, and L. Corey. 2002. Virus population homogenization following acute human immunodeficiency virus type 1 infection. J. Virol. 76:11953-11959.
27. Liu, S. L., A. G. Rodrigo, R. Shankarappa, G. H. Learn, L. Hsu, O. Davidov, L. P. Zhao, and J. I. Mullins. 1996. HIV quasispecies and resampling. Science 273:415-416.
28. Livak, K. J., S. J. Flood, J. Marmaro, W. Giusti, and K. Deetz. 1995. Oligonucleotides with fluorescent dyes at opposite ends provide a quenched probe system useful for detecting PCR product and nucleic acid hybridization. PCR Methods Appl. 4:357-362.
29. Malet, I., M. Belnard, H. Agut, and A. Cahour. 2003. From RNA to quasi-species: a DNA polymerase with proofreading activity is highly recommended for accurate assessment of viral diversity. J. Virol. Methods 109:161-170.
30. Mansky, L. M., and H. M. Temin. 1995. Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase. J. Virol. 69:5087-5094.
31. Mellors, J., S. Palmer, D. Nissley, M. Kearney, E. Halvas, C. Bixby, L. Demeter, S. Eshleman, K. Bennett, F. Vaida, J. Coffin, and S. Hammer. 2003. Low frequency nonnucleoside reverse transcriptase inhibitor (NNRTI)-resistant variants contribute to failure of efavirenz-containing regimens in NNRTI-experienced patients with negative standard genotypes for NNRTI genotypes. Antivir. Ther. 8:S150.
32. Menendez-Arias, L. 2002. Molecular basis of fidelity of DNA synthesis and nucleotide specificity of retroviral reverse transcriptases. Prog. Nucleic Acid Res. Mol. Biol. 71:91-147.
33. Metzner, K. J., S. Bonhoeffer, M. Fischer, R. Karanicolas, K. Allers, B. Joos, R. Weber, B. Hirschel, L. G. Kostrikis, H. F. Günthard, et al. 2003. Emergence of minor populations of human immunodeficiency virus type 1 carrying the M184V and L90M mutations in subjects undergoing structured treatment interruptions. J. Infect. Dis. 188:1433-1443.
34. Nájera, I., A. Holguín, M. E. Quiñones-Mateu, M. A. Muñoz-Fernández, R. Nájera, C. López-Galíndez, and E. Domingo. 1995. pol gene quasispecies of human immunodeficiency virus: mutations associated with drug resistance in virus from patients undergoing no drug therapy. J. Virol. 69:23-31.
35. Palmer, S., M. Kearney, F. Maldarelli, S. Kottilil, D. Lucey, J. Metcalf, D. Rock, M. VanHoutte, L. Michels, K. Hertogs, J. Mellors, and J. Coffin. 2002. Genetics of HIV-1 populations in acute and chronic infection. Antivir. Ther. 7:S57.
36. Paul, S. M., and V. S. Jorden. 2003. HIV resistance testing. A clinical tool. N. J. Med. 100:44-49. (Quiz, 100:75-76).
37. Preston, B. D., B. J. Poiesz, and L. A. Loeb. 1988. Fidelity of HIV-1 reverse transcriptase. Science 242:1168-1171.
38. Richman, D. D., D. Havlir, J. Corbeil, D. Looney, C. Ignacio, S. A. Spector, J. Sullivan, S. Cheeseman, K. Barringer, D. Pauletti, C.-K. Shih, M. Myers, and J. Griffin. 1994. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J. Virol. 68:1660-1666.
39. Roberts, J. D., K. Bebenek, and T. A. Kunkel. 1988. The accuracy of reverse transcriptase from HIV-1. Science 242:1171-1173.
40. Schuurman, R., D. Brambilla, T. de Groot, D. Huang, S. Land, J. Bremer, I. Benders, and C. A. Boucher. 2002. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res. Hum. Retrovir. 18:243-248.
41. Shafer, R. W., M. A. Winters, S. Palmer, and T. C. Merigan. 1998. Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated HIV-1 infected patients. Ann. Intern. Med. 128:906-911.
42. Shankarappa, R., P. Gupta, G. H. Learn, Jr., A. G. Rodrigo, C. R. Rinaldo, Jr., M. C. Gorry, J. I. Mullins, P. L. Nara, and G. D. Ehrlich. 1998. Evolution of human immunodeficiency virus type 1 envelope sequences in infected individuals with differing disease progression profiles. Virology 241:251-259.
43. Shankarappa, R., J. B. Margolick, S. J. Gange, A. G. Rodrigo, D. Upchurch, H. Farzadegan, P. Gupta, C. R. Rinaldo, G. H. Learn, X. He, X. L. Huang, and J. I. Mullins. 1999. Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J. Virol. 73:10489-10502.
44. Simmonds, P., P. Balfe, C. A. Ludlam, J. O. Bishop, and A. J. Brown. 1990. Analysis of sequence diversity in hypervariable regions of the external glycoprotein of human immunodeficiency virus type 1. J. Virol. 64:5840-5850.
45. Svarovskaia, E. S., S. R. Cheslock, W. H. Zhang, W. S. Hu, and V. K. Pathak. 2003. Retroviral mutation rates and reverse transcriptase fidelity. Front. Biosci. 8:d117-d134.
46. Thompson, J. D., D. G. Higgins, and T. J. Gibson. 1994. CLUSTALW: improving the sensitivity of progressive multiple-sequence alignment through sequence weighting, position-specific gap penalties, and weight matrix choice. Nucleic Acids Res. 22:4673-4680.
47. Winters, M. A., J. M. Schapiro, J. Lawrence, and T. C. Merigan. 1998. Human immunodeficiency virus type 1 protease genotypes and in vitro protease inhibitor susceptibilities of isolates from individuals who were switched to other protease inhibitors after long-term saquinavir treatment. J. Virol. 72:5303-5306.
48. Zhang, L. Q., P. Simmonds, C. A. Ludlam, and A. J. Brown. 1991. Detection, quantification and sequencing of HIV-1 from the plasma of seropositive individuals and from factor VIII concentrates. AIDS 5:675-681.